Galderma and Chugai Announce Global License Agreement for Nemolizumab, Novel Biotherapy for Skin Diseases
Lausanne, 21 July 2016 - Galderma, Nestlé Skin Health’s medical solutions business, today announced that it has entered into a global license agreement with Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) for “nemolizumab” (CIM331) the anti-IL-31 receptor A humanized monoclonal antibody created by Chugai, which is currently under development for atopic dermatitis and pruritus in hemodialysis patients.
Under the terms of the agreement, Chugai will grant Galderma an exclusive license for the development and marketing of nemolizumab worldwide, with the exception of Japan and Taiwan. Chugai will continue to be responsible for product manufacturing and supply of nemolizumab.
Humberto C. Antunes, Chief Executive Officer of Nestlé Skin Health: “This strategic alliance is a key milestone in our mission to enhance the quality of life of people by addressing unmet skin health needs. It allows Galderma, our medical solutions business, to expand its portfolio with a new innovative biotherapy candidate for patients with moderate-to-severe atopic dermatitis.”
Dr. Johannes J. Baensch, Chief Scientific Officer of Nestlé Skin Health: “This marks our commitment to make the most advanced technologies available to the dermatology medical community, meeting patient needs and healthcare professional expectations. We will develop these innovative treatment options by building on the competences of our experienced international teams, leveraging state of the art knowledge in dermatology research and global clinical development capacities.”
Head of Corporate Communications, Nestlé Skin Health